Have You Or Has Someone In Your Family Been Diagnosed With Ovarian Cancer?
Did you know that 1 in 4 women diagnosed with ovarian cancer have the KRAS-variant, an inherited gene mutation that provides information about an individual’s additional cancer risk, as well as how they will respond to specific medical treatments?
You may be eligible for one of several studies that determines if you have the KRAS-variant, information that can be used to help you make the best decisions for you health.
What we know about the KRAS-variant:
- Found in 6-10% of the population
- Predicts sensitivity and resistance to several standard-of-care cancer treatments/therapies
- Associated with a lifetime risk of breast cancer of > 20%, supporting eligibility for higher-level screening
- Explains the genetic cause of cancer for over 50% of Hereditary Breast and Ovarian Cancer (HBOC) families with no other known genetic markers
- Associated primarily with post-menopausal ovarian cancer, enabling the opportunity for cancer prevention through informed decision making about ophorectomy (ovarian removal) at menopause
The KRAS-variant is one of the most powerful known, inherited genetic markers associated with cancer. The latest research indicates the KRAS-variant shows great potential to guide disease prevention and management across cancer types through its unique interactions with hormones and cancer therapies.
TAKE THE ELIGIBILITY SURVEY
We encourage you to see if you are eligible to join a MiraKind study to help us discover meaningful ways to better treat patients with genetic mutations. If you would like to join a study, please click the button below. You will be able to choose to get your KRAS-variant results at a discounted cost ($195) through the study. If you would prefer to directly order KRAS-variant testing at cost ($295) without joining a study, please follow this link.
MiraKind’s pipeline of planned and ongoing research studies are designed to protect the health of individuals with the KRAS-variant and to help answer the most pressing questions about cancer.
Research questions include:
- What are the best cancer management strategies for KRAS-variant cancer
- What environmental factors, hormone exposures, medicines, or other lifestyle factors can influence cancer risk for individuals with the KRAS-variant?
- How do individuals with the KRAS-variant respond differently to factors like hormone replacement therapy, birth control, or IVF?
- How can cancer survivors who are positive for the KRAS-variant protect themselves from secondary cancers?
- How can we prevent cancers associated with the KRAS-variant for family members who are positive but have never been diagnosed with cancer?